The ironic thing is I agree with him on quite a few things. We...

The ironic thing is I agree with him on quite a few things. We can all unequivocally agree Sector was an impediment to any constructive discussion of CYP on here (and a pain to MSB posters), and accordingly negatively effected its share price, being a predominantly retail held stock. Take a look at the volumes, it might well be be him who has sold it down since his absence in April and May, if his bravado of his shareholdings true. Ironic if one of his long standing antagonists above buying in from him!

I am as scathing of management as Pledge and other Hot Copper commentators. Washer is a fairly listless snout at the trough (as he is in another company I am in) who clearly, along with the board, has strategically made some awful governance decisions. The evidence says so as they have ultimately stewarded the company and investor capital from a $200 million Sumitomo takeover in 2019 to a poorly timed and executed capital raise that has driven the stock to as low as $23 million. The one thing Ross and co. did do well is sort a NIHMC funded and Sydney University sponsorship of its Phae 3 knee OA trial (and the proposed Leiden University Medical Centre funded renal transplantation clinical trial, albeit only phase 1).

But lets get back to the subject this post is meant to be 9/15 (60%), 2-year survival rates in srGvHD, is a great result, if only a small phase 1 study. No way big Pharma, including Sumitomo, unaware of these results. Its ultimately using not dissimilar Mesenchymal approaches to GvHD as Mesoblast so a small reconfirmation of the shown efficacy of its GvHD results. The FDA cannot ignore this tide of prove for Msenchymal based treatment of srGvHD. As Ross and co. point out Jakavi (Ruxolitinib), recently released in Australia, shows 18-month overall survival rates of only 38% in the group which could probably be extrapolated to 30%. 60% survival by Cymerus very good news for both the company in it Phase 2 trial, and patients.